Prognostic implication and intratumoral heterogeneity of p53, Ki-67, CEA and CA19-9 expressions in cholangiocellular carcinoma

Hepatology Research

Volumn 8, Issue 2, 1997, Pages 81-94

  Takamori, Shigeru ^a   Yoshimoto, Jiro ^a   Kojima, Kuniaki ^a   Matsumoto, Toshiharu ^a   Beppu, Tomoe ^a   Futagawa, Shunji ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

CA19 9; CEA; Cholangiocellular carcinoma; Ki 67; p53; Prognosis

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; KI 67 ANTIGEN; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER LOCALIZATION; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAPAN; LABELING INDEX; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION;

EID: 0030868531     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6346(97)00054-5     Document Type: Article

References (44)

1. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
2. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992;71:875-86.
3. Lane DP. p53, guardian of the genome. Nature 1992;358:15-6.
4. Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chrom Cancer 1992;4:1-15.
5. Dyson N, Howley PM, Münger K, Harlow ED. The human papilloma virus-16 E7 oncoprotein is able to bind the retinoblastoma gene product. Science 1989;243:934-7.
6. Puisieux A, Ji J, Guillot C, Legros Y, Soussi T, Isselbacher K, Ozturk M. p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. Proc Natl Acad Sci USA 1995;92:1342-6.
7. Reich NC, Oren M, Levine AJ. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol 1983;3:2143-50.
8. Remivikos Y, Tominaga O, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B, et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992;66:758-64.
9. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-54.
10. Fonseca L, Yonemura Y, Aretxabala XD, Yamaguchi A, Miwa K, Miyazaki I. p53 detection as a prognostic factor in early gastric cancer. Oncology 1994;51:485-90.
11. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994;54:4667-70.
12. Terada T, Shimizu K, Izumi R, Nakanuma Y. p53 expression in formalin-fixed, paraffin embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections. Mod Pathol 1994;7:249-52.
13. Warnakulasuriya KAAS, Johnson NW. Association of overexpression of p53 oncoprotein with the state of cell proliferation in oral carcinoma. J Oral Pathol Med 1994;23:246-50.
14. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
15. Youssef EM, Matsuda T, Takada N, Osugi H, Higashino M, Kinoshita H, et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer 1995;76:358-66.
16. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM, et al. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 1992;66:373-85.
17. Moch H, Sauter G, Mihatsch MJ, Gudat F, Epper R, Waldman FM. p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Hum Pathol 1994;25:1346-51.
18. Nagao T, Kondo F, Sato T, Nagao Y, Kondo Y. Immunohistochemical detection of aberrant p53 expression in hepatocellular carcinoma. Hum Pathol 1995;26:326-33.
19. Hamada Y, Yamamura M, Hioki K, Yamamoto M, Nagura H, Watanabe K. Immunohistochemical study of carcinoembryonic antigen in patients with colorectal cancer. Cancer 1985;55:136-41.
20. Teixeira CR, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, et al. Carcinoembryonic antigen staining patterns at the invasive tumor margin predict the malignant potential of colorectal carcinoma. Oncology 1994;51:228-33.
21. Kawamoto T, Saitou K, Todoroki T, Koike N, Kanazawa N, Iwasaki Y, et al. Immunohistochemical detection of proliferating cell nuclear antigen (PCNA) in carcinoma at the confluence of the main hepatic ducts and its relationship to expression of CEA, CA 19-9 and EGF receptor. Jpn J Gastroenterol (in Japanese) 1993;90:14-153.
22. Ohta T, Nagakawa T, Fonseca L, Yoshimitsu Miyazaki I, Terada T. Stromal distribution of CA19-9 as a predictor of lymph node metastases in gallbladder cancer without serosal invasion. Oncology 1994;51:238-43.
23. Ichihara T, Naruga H, Nakao A, Sakamoto J, Watanabe T, Takagi H. Immunohistochemical localization of CA 19-9 and CEA in pancreatic carcinoma and associated diseases. Cancer 1988;61:324-33.
24. Asagoe T, Yamamoto H, Hanatani Y, Horie F, Nemoto A, Kidooka K, et al. A clinicopathological study on carcinoembryonic antigen in breast cancer. J Jpn Soc Cancer Ther (in Japanese) 1990;25:793-8.
25. Haraguchi M, Okamura T, Korenaga D, Tsujitani S, Martin P, Sugimachi K. Heterogeneity of DNA ploidy in paffents with undifferentiated carcinomas of the stomach. Cancer 1987;59:922-4.
26. El-Naggar AK, Garcia GM. Epithelioid sarcoma. Flow cytometric study of DNA content and regional DNA heterogeneity. Cancer 1992;69:1721-8.
27. Suto T, Sasaki K, Sugai T, Kanno S, Saito K. Heterogeneity in nuclear DNA content of cells in carcinomas of the biliary tract and pancreas. Cancer 1993;72:2920-8.
28. Liver Cancer Study Group of Japan. The General Rules for the Clinical and Pathological Study of Primary Liver Cancer (in Japanese). 3rd ed. Tokyo: Kanehara Publicaffon, 1992.
29. Cattoreffl G, Becker MHG, Key G, Duchrow M, Schlüter C, Galle J, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-63.
30. Szekeres G, de Giacomoni P. Ki-67 and p53 expression in cutaneous Bowen's disease: an immunohistochemical study of fixed-embedded tissue sections. Acta Derm Venerol (Stockh) 1994;74:95-7.
31. Shi S-R, Key ME, Kalra KL. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven healing of tissue sections. J Histochem Cytochem 1991;39:741-8.
32. Yamaguchi A, Makimoto K, Goi T, Takeuchi K, Maehara M, Isobe Y, et al. Overexpression of p53 protein and proliferative activity in colorectal adenoma. Oncology 1994;51:224-7.
33. Steinbeck RG, Heselmeyer KM, Moberger HB, Auer GU. The relationship between proliferating cell nuclear antigen (PCNA), nuclear DNA content and mutant p53 during genesis of cervical carcinoma. Acta Oncol 1995;34:171-5.
34. Wynford-Thomas D. p53 in tumor pathology: can we trust immunocytochemistry?. J Pathol 1992;166:329-30.
35. Eyfjörd JE, Thorlacius S, Steinarsdottir M, Valgardsdottir R, Ogmundsdottir HM, Anamthawat Jonsson K. p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 1995;55:646-51.
36. Vähäkangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP, et al. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 1992;339:576-80.
37. Shiao Y-H, Rugge M, Correa P, Lehmann HP, Scheer WD. p53 alteration in gastric precancerous lesions. Am J Pathol 1994;144:511-7.
38. Brambilla E, Gazzeri S, Moro D, de Fromentel CC, Gouyer V, Jacrot M, et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993;143:199-210.
39. Villuendas R, Piris MA, Orradre JL, Mollejo M, Algara P, Sanchez L, et al. p53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol 1992;166:235-41.
40. Rizzi PM, Ryder SD, Portmann B, Ramage JK, Naoumov NV, Williams R. p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut 1996;38:265-8.
41. Minato H, Nakanuma Y. Cell kinetic and morphological studies of human cholangiocellular carcinoma. Acta Pathol Jpn 1993;43:111-120.
42. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, et al. Overexpression and mutation of TP53 in ovarian cancer. Cancer Res 1991;51:2979-84.
43. Skomedal H, Kristensen G, Helland Å, Nesland JM, Kooi S, Børresen A-L, et al. TP53 gene mutations and protein accumulation in primary vaginal carcinomas. Br J Cancer 1995;72:129-33.
44. Yoshida Y. A correlation between mutation of the p53 gene and histological heterogeneity in differentiated adenocarcinomas of the lung, with reference to stepwise progression and metastatic ability. Hiroshima J Med Sci 1994;43:13-21.